Famocid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Famocid

Property Description
Active ingredient Famotidine
Form Tablets, Oral Suspension, Injection Solution
Pharmacological Class Histamine H₂-receptor Antagonist
General Purpose Gastric Acid Secretion Inhibitor
Origin Synthetic Compound

What Type of Medicine is Famocid (Famotidine)?

Famocid is a synthetic compound containing the active ingredient Famotidine, which functions as a highly specific Histamine H₂-receptor antagonist. This classification places the drug within the therapeutic group of anti-secretory agents that act as an acid reducer. Famotidine is considered a second-generation compound in its class, known for its targeted action. This positioning is clinically recognized as offering a reduced potential for drug interactions compared to earlier H₂-blockers. The medicine acts to create a less acidic environment within the stomach by precisely blocking the H₂ receptors found on stomach cells, thereby preventing the signals that trigger acid production.

Composition, Forms, and General Therapeutic Purpose

The medicine is composed of the single-ingredient product Famotidine, along with necessary pharmaceutical excipients for stability and presentation. To accommodate different clinical needs, the active compound is made available in multiple pharmaceutical preparations, including common solid tablets, liquid oral suspension, and a solution for injection, establishing its routes of administration as both oral and parenteral. The overarching general purpose of this pharmaceutical is the reliable and sustained inhibition of gastric acid secretion. By suppressing both the concentration and the volume of gastric juice, the compound provides a foundational therapeutic benefit, often used to manage a typical scenario such as general discomfort and irritation caused by excessive stomach acid.

Regulatory References

  1. Famotidine
  2. pharmacological studies
  3. Famotidine

What side effects are possible with Famocid?

Possible side effects and safety information

The official safety profile for Famocid (famotidine) classifies documented adverse reactions by frequency and affected physiological system, based on governmental regulatory standards. The majority of observed reactions primarily involve the Nervous System and Gastrointestinal tract.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized according to standard regulatory definitions:

Classification Examples of Reactions
Common Headache, Dizziness, Constipation, Diarrhea
Uncommon Nausea, Vomiting, Abdominal discomfort/pain, Rash, Fatigue
Rare / Not Known Confusion, Arrhythmia, Cholestatic Jaundice, Interstitial Nephritis, Severe Hypersensitivity Reactions

Documented Serious Adverse Reactions

Regulatory documents explicitly highlight rare, but clinically significant, outcomes including Severe Hypersensitivity Reactions (such as anaphylaxis and angioedema) and Severe Blood Dyscrasias (e.g., agranulocytosis, thrombocytopenia). Serious Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome, are also noted in the safety framework.

Population-Specific Safety Considerations

The official labeling notes specific safety considerations for certain patient groups. Older adults and patients with Renal Impairment have a documented increased susceptibility to Central Nervous System (CNS) adverse reactions, such as confusion or hallucinations, due to altered clearance of the active compound.

Safety Restrictions

The medicine is Contraindicated in individuals with a known hypersensitivity to Famotidine or other H₂-receptor antagonists. Furthermore, official documents note that use requires caution in the presence of a known or suspected gastric malignancy, as symptom relief may potentially mask symptoms of the underlying condition.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Famocid (famotidine) overdose as primarily involving an exaggeration of known adverse effects. These dose-dependent manifestations have included symptoms such as restlessness, vomiting, and tachycardia (abnormally rapid heart rate). More severe central nervous system (CNS) effects, including confusion, disorientation, hallucinations, and even seizures have been documented, especially in susceptible individuals.


Required Emergency Actions

The regulatory profile mandates specific actions in the event of suspected overexposure. The most critical instruction is to seek immediate medical help or contact a Poison Control Center right away. Immediate medical attention is required if the individual collapses, has a seizure, cannot be awakened, or experiences trouble breathing. Treatment is officially designated as symptomatic and supportive, as no specific antidote is known for Famotidine overdose.


Population-Specific Considerations

Official labeling identifies specific patient populations at increased risk of experiencing adverse effects from elevated systemic exposure. Patients with moderate to severe renal impairment and elderly individuals are noted for their heightened susceptibility to CNS adverse reactions due to reduced drug clearance. Close clinical observation and cardiac monitoring are required procedures during management.

Therapeutic Uses of Famocid

What Famocid Treats: Main Uses and Benefits

Famocid (famotidine) is applied across domains where additional symptomatic support is needed for conditions linked to excessive gastric acid. This supports the patient during difficult episodes by easing distress and managing symptoms related to systemic imbalance caused by heightened physiological activity.

Therapeutic areas involve contexts where symptomatic relief is needed for duodenal and gastric ulcers, as well as gastroesophageal reflux disease (GERD). It is considered relevant for easing symptoms that become more disruptive during flare-ups associated with conditions involving inflammatory or irritative processes such as erosive esophagitis. It is also applied in addressing pathological hypersecretory conditions, like Zollinger-Ellison syndrome.

For symptoms related to physical discomfort like episodic heartburn, a non-prescription formulation may provide support that helps ease the overall symptom burden and assists with maintaining functional stability.

“It is commonly used to help with symptomatic relief that supports patients during episodes of heightened discomfort.”

Quick Fact: May assist with symptoms related to physical discomfort

Eligibility and Restrictions for Use

Eligibility and Contraindications for Famocid

The eligibility for Famocid (Famotidine) use is strictly governed by regulatory classifications, focusing on pre-existing conditions and patient demographics. The medicine is contraindicated and must not be used by patients with a history of serious hypersensitivity reactions to Famotidine or to any other medicine in the Histamine H2-receptor antagonist class.

Population Group Regulatory Status
Renal Impairment Conditional Use is required for moderate to severe impairment; patients are at risk for increased exposure and CNS effects.
Pregnancy / Lactation Restricted Use. Generally not recommended in pregnancy unless clearly needed. Use during lactation requires a decision to discontinue the drug or nursing, as it is excreted in breast milk.
Gastric Malignancy Conditional Use. Symptom relief does not preclude cancer; pre-treatment evaluation is required.

Regarding age, use is established by the FDA for adults and certain pediatric populations (including infants). However, some regulatory bodies state that safety and efficacy in children are not established, restricting general pediatric use. Older adults may use the medicine but require monitoring due to age-related changes in renal function.

What should I know about interactions with other medicines?

Famocid (Famotidine) has a defined interaction profile governed primarily by its effect on gastric pH. These are the officially documented interaction patterns based on regulatory information.

Pharmacokinetic pH-Dependent Interactions

Famotidine's action as an acid reducer can alter the absorption of other medicines that require an acidic environment for solubility. This pharmacokinetic interaction results in a formally documented decreased plasma concentration (reduced exposure) of certain co-administered drugs. Examples explicitly listed in regulatory documents include the antiretroviral agent Atazanavir, Delavirdine, and the oral suspension formulation of Posaconazole.

Interacting Product Category Official Outcome Constraint Type
pH-Dependent Absorption Drugs Reduced absorption/exposure Timing/Separation
Antacids Reduced Famotidine absorption Timing/Separation

Administration Timing Requirements

To manage the pH-related pharmacokinetic effect, regulatory authorities mandate specific timing separation rules for certain combinations:

  • Posaconazole oral suspension: Famotidine must be administered at least three hours after the Posaconazole dose.
  • Antacids: Co-administration must be separated by one to two hours to prevent reduced absorption of Famotidine.

Metabolic and Contraindication Status

Famotidine has a minimal metabolic interaction profile, officially documented as having no clinically significant inhibition or induction of the Cytochrome P450 enzyme system. Furthermore, no combinations are formally listed as strictly contraindicated (prohibited) in major government regulatory labels based on interaction patterns.

Mechanism of Action

Histamine mathbfH2-Receptor Competitive Antagonism

Famocid operates as a highly selective competitive antagonist against the Histamine mathbfH2-receptors located on the basolateral membrane of the gastric parietal cells. This action blocks the natural binding of the endogenous mediator histamine, which is the necessary first step in the signaling cascade that stimulates acid production.

Disruption of the mathbfcAMP Signaling Cascade

By occupying the H2-receptor, Famocid prevents the subsequent internal cAMP signaling cascade from activating the cell's acid-secreting machinery. This mechanism inhibits the downstream stimulation of the Proton Pump (mathbfH^+/K^+ ATPase), which is the final common pathway for H^+ ion release.

Suppression of Gastric Acid Secretion

This molecular and cellular interference results in the primary physiological effect of suppressing gastric acid secretion, leading to a measurable, sustained reduction in the volume and hydrogen ion concentration of gastric fluid. The blockade inhibits basal, nocturnal, and stimulated acid output.

Dosage and Administration Information

How Famocid (Famotidine) is Used

Famocid is administered using regimens that depend on the condition being addressed. The medicine is available for both oral administration (as tablets or suspension) and intravenous (IV) administration (as an injection solution).


Administration and Dosing Principles

Usage Parameter Description of Usage
Standard Adult Oral Doses Regimens range from 20 mg once daily for maintenance therapy to 40 mg once daily or 20 mg twice daily for active ulcers and gastroesophageal reflux disease (GERD). Pathological hypersecretory conditions often begin with 20 mg every 6 hours.
Timing in Relation to Meals Famotidine may be taken with or without food. Once-daily doses are frequently taken before bedtime to align with therapeutic goals.
Typical Duration of Use Treatment for active ulcers or erosive esophagitis is typically time-limited, lasting up to 8 to 12 weeks. In contrast, maintenance therapy to reduce the risk of ulcer recurrence may continue for up to one year.
IV Administration Used when oral intake is not feasible, the injection must be administered slowly, typically over 15 to 30 minutes when diluted, or over a minimum of two minutes for direct injection.

Population-Specific Instructions

Dosage adjustments are established for patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min). For these individuals, the dose may be reduced, and the interval between doses may be extended to 36 to 48 hours, particularly in severe cases. No specific dose adjustment is required based solely on advanced age. If a scheduled dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next dose, in which case the subsequent dose should be taken at the usual time.

Recent Clinical Evidence

Research evidence / Overview of studies for Famocid

The research evidence for Famocid (famotidine) relies on clinical trials, including randomized controlled trials (RCTs) and long-term observational studies, which are used by regulatory bodies to assess the evidence base for the medicine’s approved uses in contexts related to excessive stomach acid.


Evidence for Approved Indications

For Duodenal and Gastric Ulcers, the evidence includes short-term RCTs that explore objective measurements of ulcer healing rates (often assessed endoscopically). Maintenance studies have also tracked patterns of ulcer reappearance over longer periods.

Research for Gastroesophageal Reflux Disease (GERD), including erosive esophagitis, has involved comparative and placebo-controlled trials. These studies primarily track patient-reported outcomes, such as symptom relief, alongside objective measures of the esophageal lining's healing rate.

For rare Pathological Hypersecretory Conditions (like Zollinger-Ellison Syndrome), research is derived from smaller clinical trials and case reports. These studies focus on monitoring the physiological endpoint of sustained gastric acid output control, exploring patterns related to required dose adjustment.

Research for Episodic Heartburn consists of short-term RCTs focusing on healthy adults, measuring how quickly symptom relief was achieved and exploring its association with the avoidance of discomfort.


Long-Term Evidence and Research Uncertainty

A key limitation across the evidence landscape is the lack of extensive long-term data extending beyond six months, particularly regarding the durability of the effect for chronic use. Research continues to explore whether the effect on acid suppression may vary over many months.

Studies have been conducted in specific groups like pediatric patients and older adults. However, data for certain complex patient subgroups, such as those with multiple comorbidities, often remains limited. The evidence highlights what is known through group patterns but does not predict individual outcomes.

Frequently Asked Questions (FAQ)

Common questions about Famocid (FAQ)


Q: Is Famocid the same kind of medicine as omeprazole or Zantac?

Famocid is classified as a Histamine H2-receptor antagonist, also commonly known as an H2-blocker. Omeprazole is from a different class called a Proton Pump Inhibitor (PPI). While both types of medicine reduce stomach acid, official documents confirm that they work through distinct biological mechanisms.


Q: Does taking Famocid affect how my body absorbs vitamins or iron?

Official regulatory documents note that because Famocid reduces stomach acidity, it may alter how the body absorbs other medicines that require an acidic environment to dissolve. The principle of pH-dependent absorption suggests a potential influence on the body's uptake of certain nutrients, such as iron.


Q: Is Famocid safe to take every day for a long time?

According to official product information, the use of Famocid is often time-limited, such as for 8 to 12 weeks for active conditions. Use for long-term maintenance therapy to prevent ulcers may be recommended for up to one year. Official labeling and studies indicate limited data are available on the effects of continued daily use extending beyond six months.


Q: How long do the effects of one dose of Famocid usually last?

Studies indicate that after taking a single oral dose of Famocid, the therapeutic effect of reducing stomach acid is sustained. This acid-suppressing effect typically lasts for approximately 10 to 12 hours.


Q: Does Famocid interact with herbal supplements or vitamins?

Official documents indicate that Famocid has a low potential for metabolic interactions because it is minimally processed by the body's major enzyme system, Cytochrome P450. However, specific interaction data on every individual supplement or herbal product is not provided in regulatory labels.


Q: Does Famocid affect mood or cause anxiety?

Official labeling reports that some patients have experienced Central Nervous System (CNS) effects, such as confusion. Official reports indicate an increased susceptibility to these effects in older adults or individuals with kidney problems. Anxiety or common mood changes are generally not listed as frequent or common adverse reactions.


Q: Does Famocid affect the immune system in any way?

The medicine’s safety profile includes rare reports of severe hypersensitivity reactions, which are a type of immune-system response. Regulatory documents also note rare occurrences of blood dyscrasias, which are conditions affecting blood cells, including those involved in the immune response.


Q: Does taking Famocid affect alertness or the ability to drive?

Because the medicine is associated with documented side effects such as dizziness and fatigue, regulatory authorities state there is a potential influence on a person’s ability to drive or operate machinery.


Q: How long does Famocid take to start working after I take it?

According to the official product information, the process of reducing stomach acid typically begins relatively quickly. Following the administration of a single oral dose, the therapeutic action starts within one hour.


Q: What is the difference between prescription Famocid and the kind I can buy over the counter?

The primary difference defined in official regulatory documents is the dosage strength and the approved uses. The over-the-counter (OTC) strengths are typically lower than prescription strengths, and their approved use is limited to short-term management of episodic symptoms.


Q: Are there any known interactions between Famocid and common pain relievers like ibuprofen?

Regulatory documents describe a minimal potential for metabolic interaction between Famocid and other commonly used medicines. This low potential includes non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen.


Q: If I stop taking Famocid suddenly, will my symptoms come back worse?

Official regulatory labeling for Famocid does not contain specific warnings about severe rebound acid hypersecretion upon sudden stopping.


Q: Is Famocid a common medicine used to treat H. pylori infection?

Official indications for Famocid do not list its use as a monotherapy, or sole treatment, for H. pylori infection. However, studies and product information indicate that it is sometimes used as an adjunct (additional medicine) within combination therapies for ulcer management.


Q: Can Famocid be used by people with a history of liver problems?

While official documents do not list specific dose adjustments for hepatic (liver) impairment, regulatory caution is recommended. This caution is primarily due to the rare potential for adverse reactions, such as cholestatic jaundice, which is related to liver function.


Q: Can Famocid be split or chewed if it's hard to swallow?

Official administration guidelines state that the tablets are generally intended to be swallowed whole. If swallowing difficulty is an issue, the liquid oral suspension formulation is officially noted as an alternative.


Q: Does alcohol consumption affect how Famocid works?

Official regulatory documents and patient information leaflets generally contain no specific warnings or known pharmacological descriptions of an interaction between Famocid and the consumption of alcohol.


Q: Can taking Famocid affect the results of other medical tests?

Official labeling notes that Famocid may potentially interfere with the accuracy of certain diagnostic tests. This includes tests that check for gastric acid secretion and specific skin prick tests used for allergy identification.


Q: Does Famocid interact with blood-thinning medicines like warfarin?

Regulatory reviews of the drug's safety profile have specifically concluded that Famocid has shown no clinically significant interaction with the blood-thinning medicine warfarin.


Q: Is the long-term use of Famocid associated with bone health concerns?

Official regulatory safety warnings indicate that, unlike some other types of acid-reducing medicines, Famocid is not associated with an increased risk of bone fracture or general concerns regarding bone mineral density.


Q: Can Famocid be taken with fruit juice, or should it only be taken with water?

Regulatory administration documents state that tablets or suspension may be taken with a glass of water. Official labels do not list any specific liquids or fruit juices that are prohibited for consumption with the medicine.

How should Famocid be stored and disposed of?

Famocid Storage and Disposal Requirements

Scope Item Official Regulatory Requirement
Labeled storage temperature requirements: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F).
Light/moisture protection requirements: Must be protected from light and moisture.
Stability after opening/reconstitution: Discard unused constituted Oral Suspension after 30 days from the date it was mixed.
Handling requirements: The Oral Suspension must be protected from freezing.
Packaging-related storage rules: Tablets should be stored in the original package and the container must be tightly closed.
Disposal instructions: Dispose of unused medicinal product or waste material in accordance with local requirements.
Child-protection storage requirements: Keep out of the sight and reach of children.

These instructions define the mandatory storage constraints, requiring temperature control and protection from environmental factors like light, moisture, and freezing. The specific discard date for the mixed liquid suspension is a critical stability requirement. All disposal of unused product must strictly adhere to local regulatory waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Famocid found in:

A-Z Index: